Cargando…

Comparative Effectiveness of Abatacept Versus Tumor Necrosis Factor Inhibitors in Patients with Rheumatoid Arthritis Who Are Anti-CCP Positive in the United States Corrona Registry

INTRODUCTION: Anti-citrullinated protein antibodies (ACPAs) are highly specific serological biomarkers that are indicative of a poor prognosis in patients with rheumatoid arthritis (RA). The effectiveness of biologic disease-modifying antirheumatic drugs (bDMARDs) with different mechanisms of action...

Descripción completa

Detalles Bibliográficos
Autores principales: Harrold, Leslie R., Litman, Heather J., Connolly, Sean E., Alemao, Evo, Kelly, Sheila, Rebello, Sabrina, Hua, Winnie, Kremer, Joel M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6513934/
https://www.ncbi.nlm.nih.gov/pubmed/30868550
http://dx.doi.org/10.1007/s40744-019-0149-3
_version_ 1783417792665485312
author Harrold, Leslie R.
Litman, Heather J.
Connolly, Sean E.
Alemao, Evo
Kelly, Sheila
Rebello, Sabrina
Hua, Winnie
Kremer, Joel M.
author_facet Harrold, Leslie R.
Litman, Heather J.
Connolly, Sean E.
Alemao, Evo
Kelly, Sheila
Rebello, Sabrina
Hua, Winnie
Kremer, Joel M.
author_sort Harrold, Leslie R.
collection PubMed
description INTRODUCTION: Anti-citrullinated protein antibodies (ACPAs) are highly specific serological biomarkers that are indicative of a poor prognosis in patients with rheumatoid arthritis (RA). The effectiveness of biologic disease-modifying antirheumatic drugs (bDMARDs) with different mechanisms of action may vary, based on patients’ serostatus. The aim of this study is to compare the effectiveness of abatacept versus tumor necrosis factor inhibitors (TNFis) in patients with RA who were anti-cyclic citrullinated peptide antibody positive (anti-CCP+). METHODS: Abatacept or TNFi initiators with anti-CCP+ status (≥ 20 U/ml) at or prior to treatment initiation were identified from a large observational US cohort (1 December 2005–31 August 2016). Using propensity score matching (1:1), stratified by prior TNFi use (0, 1 and ≥ 2), effectiveness at 6 months after initiation was evaluated. Primary outcome was mean change in Clinical Disease Activity Index (CDAI) score. Secondary outcomes included achievement of remission (CDAI ≤ 2.8), low disease activity/remission (CDAI ≤ 10), modified American College of Rheumatology 20/50/70 responses and mean change in modified Health Assessment Questionnaire score. RESULTS: After propensity score matching, the baseline characteristics between 330 pairs of abatacept and TNFi initiators (biologic naïve, n = 97; TNFi experienced, n = 233) were well balanced with absolute value standardized differences of ≤ 0.1. Both overall, and in the biologic-naïve cohort, there were no significant differences in mean change in CDAI score at 6 months. However, in the TNFi-experienced cohort, there was a significantly greater improvement in CDAI score at 6 months with abatacept versus TNFi initiators (p = 0.033). Secondary outcomes showed similar trends. CONCLUSIONS: Improvements in clinical disease activity were seen in anti-CCP+ abatacept and TNFi initiators. TNFi-experienced anti-CCP+ patients with RA had more improvement in disease activity with abatacept versus TNFis, whereas outcomes were similar between treatments in the overall population and in biologic-naïve patients. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT01625650. FUNDING: This study is sponsored by Corrona, LLC and funded by Bristol-Myers Squibb. Bristol-Myers Squibb funded the publication of this manuscript. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s40744-019-0149-3) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-6513934
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Springer Healthcare
record_format MEDLINE/PubMed
spelling pubmed-65139342019-05-29 Comparative Effectiveness of Abatacept Versus Tumor Necrosis Factor Inhibitors in Patients with Rheumatoid Arthritis Who Are Anti-CCP Positive in the United States Corrona Registry Harrold, Leslie R. Litman, Heather J. Connolly, Sean E. Alemao, Evo Kelly, Sheila Rebello, Sabrina Hua, Winnie Kremer, Joel M. Rheumatol Ther Original Research INTRODUCTION: Anti-citrullinated protein antibodies (ACPAs) are highly specific serological biomarkers that are indicative of a poor prognosis in patients with rheumatoid arthritis (RA). The effectiveness of biologic disease-modifying antirheumatic drugs (bDMARDs) with different mechanisms of action may vary, based on patients’ serostatus. The aim of this study is to compare the effectiveness of abatacept versus tumor necrosis factor inhibitors (TNFis) in patients with RA who were anti-cyclic citrullinated peptide antibody positive (anti-CCP+). METHODS: Abatacept or TNFi initiators with anti-CCP+ status (≥ 20 U/ml) at or prior to treatment initiation were identified from a large observational US cohort (1 December 2005–31 August 2016). Using propensity score matching (1:1), stratified by prior TNFi use (0, 1 and ≥ 2), effectiveness at 6 months after initiation was evaluated. Primary outcome was mean change in Clinical Disease Activity Index (CDAI) score. Secondary outcomes included achievement of remission (CDAI ≤ 2.8), low disease activity/remission (CDAI ≤ 10), modified American College of Rheumatology 20/50/70 responses and mean change in modified Health Assessment Questionnaire score. RESULTS: After propensity score matching, the baseline characteristics between 330 pairs of abatacept and TNFi initiators (biologic naïve, n = 97; TNFi experienced, n = 233) were well balanced with absolute value standardized differences of ≤ 0.1. Both overall, and in the biologic-naïve cohort, there were no significant differences in mean change in CDAI score at 6 months. However, in the TNFi-experienced cohort, there was a significantly greater improvement in CDAI score at 6 months with abatacept versus TNFi initiators (p = 0.033). Secondary outcomes showed similar trends. CONCLUSIONS: Improvements in clinical disease activity were seen in anti-CCP+ abatacept and TNFi initiators. TNFi-experienced anti-CCP+ patients with RA had more improvement in disease activity with abatacept versus TNFis, whereas outcomes were similar between treatments in the overall population and in biologic-naïve patients. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT01625650. FUNDING: This study is sponsored by Corrona, LLC and funded by Bristol-Myers Squibb. Bristol-Myers Squibb funded the publication of this manuscript. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s40744-019-0149-3) contains supplementary material, which is available to authorized users. Springer Healthcare 2019-03-13 /pmc/articles/PMC6513934/ /pubmed/30868550 http://dx.doi.org/10.1007/s40744-019-0149-3 Text en © The Author(s) 2019 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Original Research
Harrold, Leslie R.
Litman, Heather J.
Connolly, Sean E.
Alemao, Evo
Kelly, Sheila
Rebello, Sabrina
Hua, Winnie
Kremer, Joel M.
Comparative Effectiveness of Abatacept Versus Tumor Necrosis Factor Inhibitors in Patients with Rheumatoid Arthritis Who Are Anti-CCP Positive in the United States Corrona Registry
title Comparative Effectiveness of Abatacept Versus Tumor Necrosis Factor Inhibitors in Patients with Rheumatoid Arthritis Who Are Anti-CCP Positive in the United States Corrona Registry
title_full Comparative Effectiveness of Abatacept Versus Tumor Necrosis Factor Inhibitors in Patients with Rheumatoid Arthritis Who Are Anti-CCP Positive in the United States Corrona Registry
title_fullStr Comparative Effectiveness of Abatacept Versus Tumor Necrosis Factor Inhibitors in Patients with Rheumatoid Arthritis Who Are Anti-CCP Positive in the United States Corrona Registry
title_full_unstemmed Comparative Effectiveness of Abatacept Versus Tumor Necrosis Factor Inhibitors in Patients with Rheumatoid Arthritis Who Are Anti-CCP Positive in the United States Corrona Registry
title_short Comparative Effectiveness of Abatacept Versus Tumor Necrosis Factor Inhibitors in Patients with Rheumatoid Arthritis Who Are Anti-CCP Positive in the United States Corrona Registry
title_sort comparative effectiveness of abatacept versus tumor necrosis factor inhibitors in patients with rheumatoid arthritis who are anti-ccp positive in the united states corrona registry
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6513934/
https://www.ncbi.nlm.nih.gov/pubmed/30868550
http://dx.doi.org/10.1007/s40744-019-0149-3
work_keys_str_mv AT harroldleslier comparativeeffectivenessofabataceptversustumornecrosisfactorinhibitorsinpatientswithrheumatoidarthritiswhoareanticcppositiveintheunitedstatescorronaregistry
AT litmanheatherj comparativeeffectivenessofabataceptversustumornecrosisfactorinhibitorsinpatientswithrheumatoidarthritiswhoareanticcppositiveintheunitedstatescorronaregistry
AT connollyseane comparativeeffectivenessofabataceptversustumornecrosisfactorinhibitorsinpatientswithrheumatoidarthritiswhoareanticcppositiveintheunitedstatescorronaregistry
AT alemaoevo comparativeeffectivenessofabataceptversustumornecrosisfactorinhibitorsinpatientswithrheumatoidarthritiswhoareanticcppositiveintheunitedstatescorronaregistry
AT kellysheila comparativeeffectivenessofabataceptversustumornecrosisfactorinhibitorsinpatientswithrheumatoidarthritiswhoareanticcppositiveintheunitedstatescorronaregistry
AT rebellosabrina comparativeeffectivenessofabataceptversustumornecrosisfactorinhibitorsinpatientswithrheumatoidarthritiswhoareanticcppositiveintheunitedstatescorronaregistry
AT huawinnie comparativeeffectivenessofabataceptversustumornecrosisfactorinhibitorsinpatientswithrheumatoidarthritiswhoareanticcppositiveintheunitedstatescorronaregistry
AT kremerjoelm comparativeeffectivenessofabataceptversustumornecrosisfactorinhibitorsinpatientswithrheumatoidarthritiswhoareanticcppositiveintheunitedstatescorronaregistry